<DOC>
	<DOCNO>NCT00612105</DOCNO>
	<brief_summary>The purpose study evaluate efficacy retigabine vs. placebo reduce pain associate post-herpetic neuralgia .</brief_summary>
	<brief_title>Safety/Efficacy Study Retigabine v . Placebo Post-Herpetic Neuralgia ( PHN )</brief_title>
	<detailed_description>This Phase 2a proof concept study evaluate safety/efficacy retigabine vs. placebo patient post-herpetic neuralgia . After screen , patient enter maximum 6 week titration period follow 4 week maintenance period 3 week taper phase .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Ability provide inform consent Male female subject 1885 year age PHN 6 month heal herpes zoster skin rash Has pain score screen randomization qualify Other significant pain may potentially confound PHN pain assessment Previous neurolytic neurosurgical therapy PHN Subject evidence progressive central nervous system ( CNS ) disease ( e.g . CNS lupus , tumor , multiple sclerosis , Alzheimer 's ) , lesion , encephalopathy Significant psychiatric neuropsychiatric disorder include limited severe depression , bipolar disorder schizophrenia spectrum disorder , history suicide attempt , recent history suicidal ideation Has clinically significant abnormality physical examination , vital sign , ECG , laboratory test screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Postherpetic Neuralgia , PHN , Shingles ,</keyword>
</DOC>